Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
![]() |
Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumorsEndocrine-related cancer, 2016-09, Vol.23 (9), p.759-767 [Peer Reviewed Journal]2016 Society for Endocrinology ;2016 Society for Endocrinology. ;ISSN: 1351-0088 ;EISSN: 1479-6821 ;DOI: 10.1530/ERC-16-0147 ;PMID: 27552969Full text available |
2 |
Material Type: Article
|
![]() |
A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in bloodAnnals of oncology, 2020-02, Vol.31 (2), p.202-212 [Peer Reviewed Journal]2019 European Society for Medical Oncology ;Copyright © 2019 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. ;ISSN: 0923-7534 ;ISSN: 1569-8041 ;EISSN: 1569-8041 ;DOI: 10.1016/j.annonc.2019.11.003 ;PMID: 31959337Full text available |
3 |
Material Type: Article
|
![]() |
Analysis of the immune landscape of small bowel neuroendocrine tumorsEndocrine-related cancer, 2019-01, Vol.26 (1), p.119-130 [Peer Reviewed Journal]2018 Society for Endocrinology ;Copyright Society for Endocrinology & BioScientifica Ltd. Jan 2019 ;ISSN: 1351-0088 ;EISSN: 1479-6821 ;DOI: 10.1530/ERC-18-0189 ;PMID: 30400003Full text available |
4 |
Material Type: Article
|
![]() |
O-20 Phase I/IB study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancerAnnals of oncology, 2020-07, Vol.31, p.239 [Peer Reviewed Journal]ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1016/j.annonc.2020.04.073Full text available |
5 |
Material Type: Article
|
![]() |
Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasmsESMO open, 2022-02, Vol.7 (1), p.100364-100364, Article 100364 [Peer Reviewed Journal]2021 The Authors ;Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved. ;2021 The Authors 2021 ;ISSN: 2059-7029 ;EISSN: 2059-7029 ;DOI: 10.1016/j.esmoop.2021.100364 ;PMID: 34973511Full text available |
6 |
Material Type: Article
|
![]() |
Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumorsEndocrine-related cancer, 2015-02, Vol.22 (1), p.1-9 [Peer Reviewed Journal]2015 Society for Endocrinology ;2015 Society for Endocrinology. ;ISSN: 1351-0088 ;EISSN: 1479-6821 ;DOI: 10.1530/ERC-14-0360 ;PMID: 25376618Full text available |
7 |
Material Type: Article
|
![]() |
A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumorsAnnals of oncology, 2012-09, Vol.23 (9), p.2335-2341 [Peer Reviewed Journal]2012 European Society for Medical Oncology ;2015 INIST-CNRS ;The Author 2012. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2012 ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdr614 ;PMID: 22317769Full text available |
8 |
Material Type: Article
|
![]() |
A phase II study of axitinib in advanced neuroendocrine tumorsEndocrine-related cancer, 2016-05, Vol.23 (5), p.411-418 [Peer Reviewed Journal]2016 Society for Endocrinology ;2016 Society for Endocrinology. ;ISSN: 1351-0088 ;EISSN: 1479-6821 ;DOI: 10.1530/ERC-16-0008 ;PMID: 27080472Full text available |
9 |
Material Type: Article
|
![]() |
Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumorsESMO open, 2024-04, Vol.9 (4), p.102386-102386, Article 102386 [Peer Reviewed Journal]2024 The Authors ;Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. ;2024 The Authors 2024 ;ISSN: 2059-7029 ;EISSN: 2059-7029 ;DOI: 10.1016/j.esmoop.2024.102386 ;PMID: 38507897Full text available |
10 |
Material Type: Article
|
![]() |
Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)Annals of oncology, 2018-10, Vol.29, p.viii467-viii468 [Peer Reviewed Journal]2018 THE AUTHORS ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdy293.001 ;PMID: 32137198Full text available |
11 |
Material Type: Article
|
![]() |
A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patientsAnnals of oncology, 2012-05, Vol.23 (5), p.1335-1340 [Peer Reviewed Journal]2012 European Society for Medical Oncology ;2015 INIST-CNRS ;The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2012 ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdr442 ;PMID: 21994214Full text available |
12 |
Material Type: Article
|
![]() |
The commonwealth neuroendocrine tumour collaboration (CommNETs) and North American neuroendocrine tumor society (NANETS) endorsement and update of European neuroendocrine tumor society (ENETS) best practice consensus for lung neuroendocrine tumors (LNET)Annals of oncology, 2018-10, Vol.29, p.viii473-viii473 [Peer Reviewed Journal]2018 THE AUTHORS ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdy293.015 ;PMID: 32137216Full text available |
13 |
Material Type: Article
|
![]() |
Impact of liver tumor burden on therapeutic effect of 177Lu-dotatate treatment in NETTER-1 studyAnnals of oncology, 2018-10, Vol.29, p.viii471-viii471 [Peer Reviewed Journal]2018 THE AUTHORS ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdy293.009 ;PMID: 32137209Full text available |
14 |
Material Type: Article
|
![]() |
A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumorsEndocrine-related cancer, 2013-06, Vol.20 (3), p.383-390 [Peer Reviewed Journal]2013 Society for Endocrinology ;2013 Society for Endocrinology 2013 ;ISSN: 1351-0088 ;EISSN: 1479-6821 ;DOI: 10.1530/ERC-12-0390 ;PMID: 23572164Full text available |
15 |
Material Type: Article
|
![]() |
Pancreatic NETs: where do we stand now?Cancer and metastasis reviews, 2014-03, Vol.33 (1), p.361-366 [Peer Reviewed Journal]Springer Science+Business Media New York 2014 ;COPYRIGHT 2014 Springer ;ISSN: 0167-7659 ;EISSN: 1573-7233 ;DOI: 10.1007/s10555-013-9466-0 ;PMID: 24452757 ;CODEN: CMRED4Full text available |
16 |
Material Type: Article
|
![]() |
Synchronous rectal adenocarcinoma and splenic marginal zone lymphomaCurrent oncology (Toronto), 2016-02, Vol.23 (1), p.e70-74 [Peer Reviewed Journal]2016 Multimed Inc. 2016 ;ISSN: 1198-0052 ;ISSN: 1718-7729 ;EISSN: 1718-7729 ;DOI: 10.3747/co.23.2711 ;PMID: 26966416Full text available |
17 |
Material Type: Article
|
![]() |
Phase 3 Trial of Lu-177-Dotatate for Midgut Neuroendocrine TumorsThe New England journal of medicine, 2017-01, Vol.376 (2), p.125 [Peer Reviewed Journal]ISSN: 1533-4406 ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1607427Full text available |
18 |
Material Type: Article
|
![]() |
PD-2 Final result of phase IB study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancerAnnals of oncology, 2021-07, Vol.32, p.S199 [Peer Reviewed Journal]ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1016/j.annonc.2021.05.020Full text available |
19 |
Material Type: Article
|
![]() |
897P HORMONET: Phase II trial of tamoxifen for patients (pts) with estrogen/progesterone receptor (ER/PR)-positive neuroendocrine tumors (NET)Annals of oncology, 2022-09, Vol.33, p.S958 [Peer Reviewed Journal]ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1016/j.annonc.2022.07.1023Full text available |
20 |
Material Type: Article
|
![]() |
Relation between objective tumour shrinkage and progression-free survival (PFS) in the NETTER-1 populationAnnals of oncology, 2019-10, Vol.30, p.v564-v565 [Peer Reviewed Journal]ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdz256.002Full text available |